内容概要：肿瘤CRO服务是聚焦肿瘤药物研发的专业化外包服务，核心是凭借肿瘤领域专属技术能力 和合规经验，协助药企解决研发周期长、难度高、风险大等痛点，高效推进药物从临床前到上市的全流 程研发。凭藉其庞大的市场规模和显着的增长率，构成了当前CRO服务的核心领域。2024年，全球肿 瘤CRO服务市场规模从2020年的72亿美元增长至162亿美元，预计2025年全球肿瘤CRO服务市场规模将 达到186亿美元。 上市企业：百奥赛图-B[02315]、康龙化成[300759]、药明康德[603259]、美迪西[688202]、药康生物 [688046]、金斯瑞[HK.1548]、诺思格[301333] 相关企业：中美冠科、军科正源、亦康医药、北京创模、赛赋医药、北京维通达、北京昭衍、康源博 创、北京大橡科技、上海澎立生物、上海辉源生物、上海阿拉莫生物、睿智化学、上海立迪生物、禾开 生物、标度生物、上海南方模式、泰楚生物、桑迪亚、三优生物、集萃药康、南京科默医药、方达医 药、拓维生物、钧慧生物、赛业生物、华西海圻、广州源生、守正弘药、贝拓生物、格林泰科、东极生 物、有济医药、天津药物研究院、莱恩医药、凯斯艾生物、苏州兰立 ...

Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

Group 1 - A total of 59 stocks in the A-share market experienced block trading today, with a total transaction value of 1.335 billion yuan [1] - The top three stocks by transaction value were Shanxi Fenjiu (186 million yuan), Hanrui Cobalt (109 million yuan), and Jinkong Electric (80.34 million yuan) [1] - Among the stocks, 9 were traded at par, 5 at a premium, and 45 at a discount; the stocks with the highest premium rates were Bosi Software (19.41%), Jiaxun Feihong (16.8%), and Yongtai Energy (11.11%) [1] - The stocks with the highest discount rates included Zhi De Mai (20.12%), Wens Foodstuff Group (19.6%), and Nuo Si Ge (19.44%) [1] Group 2 - The ranking of institutional buy amounts was led by Shanxi Fenjiu (167 million yuan), followed by Keli'er (37.41 million yuan) and Sanfeng Intelligent (29.27 million yuan) [1] - Other notable institutional buys included Action Education (18.20 million yuan), Chunfeng Power (12.87 million yuan), and Zhi De Mai (11.47 million yuan) [1] - The top stock sold by institutional special seats was Jinkong Electric (80.34 million yuan), followed by Maiwei Co. (3.21 million yuan) [2]

| 权益类证券大宗交易(协议交易) | | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | (万股/万份) | | | | | 2025-11-18 | 301333 | 诺思格 | 48.50 | 4.28 | 207.58 | 方正证券股份有限 | 华福证券有限责任 | | | | | | | | 公司上海杨高南路 | 公司苏州分公司 | | | | | | | | 证券营业部 | | 11月18日，诺思格大宗交易成交4.28万股，成交额207.58万元，占当日总成交额的1.23%，成交价48.5 元，较市场收盘价60.2元折价19.44%。 ...

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]

Core Insights - Norska's stock price decreased by 2.00% on November 12, trading at 61.24 CNY per share with a market capitalization of 5.915 billion CNY [1] - The company has seen a year-to-date stock price increase of 22.89%, but a recent decline of 7.13% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Norska achieved a revenue of 607 million CNY, representing a year-on-year growth of 8.09% [2] - The net profit attributable to shareholders for the same period was 95.5668 million CNY, reflecting a year-on-year increase of 13.21% [2] Business Overview - Norska, established on August 22, 2008, specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2] - The revenue composition of Norska's main business includes: 39.25% from clinical trial operation services, 34.10% from clinical trial site management services, 13.30% from data management and statistical analysis services, 8.45% from biological sample testing services, 3.74% from clinical pharmacology services, and 1.16% from clinical trial consulting services [2] Shareholder Information - As of September 30, 2025, Norska had 8,734 shareholders, a decrease of 16.18% from the previous period, with an average of 6,545 circulating shares per shareholder, an increase of 19.30% [2] - The company has distributed a total of 49.4969 million CNY in dividends since its A-share listing [3]

Core Insights - The company reported steady growth in revenue and profit for Q3 2025, with a revenue of 607 million yuan for the first three quarters, representing an 8.09% year-on-year increase, and a net profit attributable to shareholders of 96 million yuan, up 13.21% year-on-year [1][2] - In Q3 2025, the company achieved a revenue of 228 million yuan, reflecting a 24.48% year-on-year growth, and a net profit of 34 million yuan, which is a 32.98% increase year-on-year [1][2] Financial Performance - For the first three quarters of 2025, sales expenses were 10.06 million yuan, down 5.77% year-on-year, while management expenses decreased significantly by 28.29% to 61.16 million yuan [3] - R&D expenses increased by 8.44% to 45.78 million yuan, with the sales expense ratio at 1.66%, down 0.24 percentage points, and the management expense ratio at 10.07%, down 5.11 percentage points [3] - In Q3 2025, sales expenses were 3.75 million yuan, up 10.64% year-on-year, while management expenses were 19.24 million yuan, down 31.80% year-on-year [3] Industry Outlook - The company is positioned to benefit from a new cycle of investment in innovative drug research and development, driven by the restructuring of valuations in the secondary market and the emergence of new exit channels for innovative drugs [3] - As a comprehensive service provider in the clinical CRO segment of the innovative drug industry chain, the company is expected to see sustained demand growth [3] Future Projections - Revenue projections for 2025-2027 are 775 million, 858 million, and 976 million yuan, with year-on-year growth rates of 4.1%, 10.8%, and 13.8% respectively [4] - Net profit projections for the same period are 121 million, 144 million, and 182 million yuan, with changes of -13.9%, +19.6%, and +26.4% respectively [4] - The current stock price corresponds to a PE ratio of 55, 46, and 36 times for 2025-2027, respectively, with a "buy" rating suggested [4]

New Stock Issuance - The stock code 300277 (海联讯) has a subscription period for acquisition rights from November 12 to November 18, 2025[1] - Stock code 603388 (*ST元成) reported severe abnormal fluctuations[1] - Stock code 002478 (常宝股份) announced a significant event with a value of 23[1] Trading Alerts - Stock code 601061 (中信金属) has a trading alert issued on November 8, 2025[1] - Stock code 600078 (澄星股份) has a trading alert issued on November 8, 2025[1] - Stock code 601179 (中国西电) has a trading alert issued on November 8, 2025[1] Abnormal Fluctuations - Stock code 000892 (欢瑞世纪) reported abnormal fluctuations on November 4, 2025[1] - Stock code 603876 (鼎胜新材) reported abnormal fluctuations on November 4, 2025[1] - Stock code 603595 (ST东尼) reported abnormal fluctuations on November 5, 2025[1]

Core Insights - The company reported a revenue of 607 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.09%, and a net profit attributable to shareholders of 96 million yuan, up 13.21% year-on-year [1] - In Q3 alone, the company achieved a revenue of 228 million yuan, marking a 24.48% increase year-on-year, and a net profit of 34 million yuan, which is a 32.98% year-on-year growth [1] Group 1: Clinical Business Recovery - The clinical business shows signs of recovery, with some order prices rebounding due to the recovery in domestic biopharmaceutical demand, leading to an increase in order volume in the CRO industry [2] - Price pressures have eased and stabilized, with some high-end clients experiencing a price increase due to the company's scientific advantages [2] - The combination of price stabilization and the company's refined management and AI technology applications is expected to further enhance gross margin levels [2] Group 2: Cost Optimization and Performance Improvement - The company has optimized its cost structure, with sales expense ratio at 1.66%, management expense ratio at 10.07%, and R&D expense ratio at 7.54% for the first three quarters of 2025 [3] - In Q3, the sales expense ratio was 1.65% (up 0.17 percentage points quarter-on-quarter), management expense ratio was 8.45% (down 2.14 percentage points quarter-on-quarter), and R&D expense ratio was 6.63% (down 1.2 percentage points quarter-on-quarter) [3] - The continuous optimization of expense ratios contributes to steady performance improvement [3] Group 3: Investment Outlook - The company is projected to achieve revenues of 782 million yuan, 873 million yuan, and 972 million yuan for 2025-2027, reflecting year-on-year growth rates of +5.1%, +11.7%, and +11.3% respectively [4] - The net profit attributable to shareholders is expected to reach 151 million yuan, 174 million yuan, and 200 million yuan for the same period, with year-on-year growth rates of +7.5%, +15.6%, and +14.7% respectively [4] - The investment rating is maintained at "Buy" [4]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported a revenue of 607 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.09%. The net profit attributable to the parent company was 96 million yuan, up 13.21% year-on-year. In Q3 alone, revenue reached 228 million yuan, a 24.48% increase year-on-year, with net profit growing by 32.98% to 34 million yuan [4] - The clinical business shows signs of recovery, with an increase in order volume and a stabilization of prices due to the recovery in domestic biopharmaceutical demand. The company is expected to see further improvements in gross margin due to refined management and the application of AI technology [4] - The company has optimized its expense structure, with sales expense ratio at 1.66%, management expense ratio at 10.07%, and R&D expense ratio at 7.54% for the first three quarters of 2025. In Q3, the sales expense ratio was 1.65%, management expense ratio decreased to 8.45%, and R&D expense ratio was 6.63% [5] Financial Projections - The company is projected to achieve revenues of 782 million yuan, 873 million yuan, and 972 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 5.1%, 11.7%, and 11.3%. The net profit attributable to the parent company is expected to be 151 million yuan, 174 million yuan, and 200 million yuan for the same years, with growth rates of 7.5%, 15.6%, and 14.7% respectively [6] - The gross margin is expected to improve from 37.1% in 2024 to 38.8% in 2027, indicating a positive trend in profitability [8]